Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19479982 | 0.84 | ALDH1A1 (0.32) | MAPTALDH1A1KDM4EHTTSLC6A3 | |
| SCHEMBL25898714 | 0.77 | GPR84 (0.32) | MAPTTSHR | |
| SCHEMBL21509731 | 0.76 | GPR84 (0.33) | MAPT | |
| SCHEMBL799308 | 0.74 | NOS3 (0.45) | TSHRALDH1A1KDM4ESLC6A3 | |
| SCHEMBL25898725 | 0.74 | GPR84 (0.36) | MAPTALDH1A1KDM4EHTT | |
| SCHEMBL21711173 | 0.74 | TSHR (0.34) | TSHR | |
| SCHEMBL21936157 | 0.73 | NOS3 (0.38) | TSHR | |
| SCHEMBL25610962 | 0.73 | — | — | |
| SCHEMBL21509894 | 0.73 | GPR84 (0.38) | MAPTALDH1A1KDM4EHTT | |
| SCHEMBL23625495 | 0.71 | POLB (0.31) | ALDH1A1HTTSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174553-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2023-06-08 | — | — | US | disclosed |
| US-20220411384-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2022-12-29 | — | — | US | disclosed |
| US-20200048267-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048267-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | MAPT 7/4885TSHR 4632/4885ALDH1A1 3839/4885 |
| US-20230174553-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | MAPT 931/4885TSHR 1662/4885ALDH1A1 4643/4885 |
| US-20220411384-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | TYK2, JAK2, STAT3 | MAPT 333/4885TSHR 1017/4885ALDH1A1 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.